Food and Drug Administration, HHS.
This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.
Name of Committee: Arthritis Advisory Committee.
General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.
Date and Time: The meeting will be held on June 2 and 3, 2004, from 8 a.m. to 5 p.m.
Location: Food and Drug Administration, Center for Drug Evaluation and Research Advisory Committee Conference Room, 5630 Fishers Lane, rm. 1066, Rockville, MD.
Contact Person: Kimberly Littleton Topper, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane, (for express delivery, 5630 Fishers Lane, rm. 1091), Rockville, MD 20857, 301-827-7001, Fax: 301-827-6801, or e-mail: email@example.com, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 3014512532. Please call the Information Line for up-to-date information on this meeting.
Agenda: On June 2, 2004, the committee will discuss trial design and endpoints for drugs for chronic gout, including new drug application (NDA) 21-740, oxypurinol (proposed tradename, OXIPRIM), Cardiome. On June 3, 2004, the committee will discuss trial design and endpoints for drugs for acute gout, including NDA 21-389, etoricoxib (proposed tradename, ARCOXIA), Merck.
Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending Start Printed Page 23795before the committee. Written submissions may be made to the contact person by May 19, 2004. Oral presentations from the public will be scheduled between approximately 1 p.m. and 2 p.m. on both days. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before May 19, 2004, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.
Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.
FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Kimberly Littleton Topper at 301-827-7001, at least 7 days in advance of the meeting.
Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).Start Signature
Dated: April 22, 2004.
William K. Hubbard,
Associate Commissioner for Policy and Planning.
[FR Doc. 04-9801 Filed 4-29-04; 8:45 am]
BILLING CODE 4160-01-S